Clinical Trial Update: Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection

View source ↗

Summary

A clinical trial evaluating nephrogenic systemic fibrosis in patients with chronic kidney disease following OptiMARK injection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Nephrogenic Systemic Fibrosis

Drugs mentioned

• OptiMARK

Snippet

Sponsor: Guerbet | Conditions: Nephrogenic Systemic Fibrosis, Renal Insufficiency | Status: WITHDRAWN